What is Rnatives?
Rnatives is a biotechnology enterprise dedicated to the advancement of small activating RNA (saRNA) therapeutics. The company operates at the intersection of molecular biology and drug discovery, utilizing a proprietary platform that targets nuclear microRNA biology to precisely modulate gene expression. This innovative approach allows for the development of targeted treatments for cardiovascular and neurological diseases, areas where traditional pharmacological interventions have historically faced significant limitations. By focusing on the fundamental mechanisms of gene regulation, Rnatives is establishing a unique competitive advantage in the life sciences landscape, aiming to address unmet clinical needs through high-precision genetic modulation.
How much funding has Rnatives raised?
Rnatives has raised a total of $3.2M across 1 funding round:
Seed
$3.2M
Seed (2025): $3.2M with participation from Nordic Science Investments Oy, Business Finland, and Force 10 Partners
Key Investors in Rnatives
Nordic Science Investments Oy
A venture capital firm specializing in deeptech and life sciences, focused on bridging the gap between academic research and commercial startup success.
Business Finland
A Finnish public organization providing innovation funding and internationalization services to support high-growth companies and national economic development.
Force 10 Partners
An advisory and investment firm that provides specialized support for corporate restructuring, complex financial challenges, and strategic growth initiatives.
What's next for Rnatives?
With the recent capital secured, Rnatives is poised to scale its operational capabilities and expand its pipeline of therapeutic candidates. The strategic focus will likely shift toward accelerating preclinical validation and preparing for initial human trials, which are critical milestones for any biotech firm operating in the gene expression space. Furthermore, the company is expected to strengthen its intellectual property portfolio and deepen its collaborative efforts with academic and clinical partners. As the firm navigates the complexities of drug development, the current financial runway provides the necessary stability to pursue long-term innovation, potentially attracting further institutional interest as it moves closer to commercialization and clinical proof-of-concept.
See full Rnatives company page
